23 November 2026 | Monday | News
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, announced that the first patient has been treated in the ASCEND study, a randomized Phase 2b trial evaluating two doses of VIS-101 (6 mg and 9 mg) head-to-head against 2 mg aflibercept in approximately 244 treatment-naïve patients with wet age-related macular degeneration (wet AMD). The study is being conducted in China in partnership with Visara, Inc., a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, Inc. (NASDAQ: NBP).
ASCEND's primary efficacy endpoint is the change in best-corrected visual acuity (BCVA) from baseline to Week 36 versus aflibercept dosed every eight weeks. The goal of the ASCEND study is to determine the dose(s) to advance into VIS-101's global Phase 3 program based on safety, efficacy and durability.
VIS-101 is a purpose-designed tetravalent, dual VEGF-A x ANG-2 inhibitor in development for retinal vascular diseases, including wet AMD, diabetic macular edema (DME) and retinal vein occlusion (RVO). In the randomized, dose ranging Phase 2a study, VIS-101 demonstrated rapid, robust, and durable treatment responses in wet AMD, along with a favorable safety profile. Approximately 50% of patients in the 6 mg treatment-naïve cohort remained retreatment-free six months after the last loading dose.
Wet AMD affects more than 20 million people globally[1]. In China, the prevalent patient population of AMD and DME exceeds 15 million, with around 600,000 new cases each year, yet only about 500,000 patients currently receive treatment.
"Patients with wet AMD and other retinal vascular diseases have significant unmet needs, as treatment burden remains a meaningful challenge for both patients and physicians," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "Dosing the first patient in the Phase 2b ASCEND study marks an important step in the clinical development of VIS-101. With encouraging efficacy, safety and durability results observed in Phase 2a, we believe VIS-101 has the potential to offer longer intervals between injections and sustained disease control. ASCEND will further evaluate this potential against an established standard of care, with findings supporting future global development.
Our established clinical and commercial capabilities across China and other Asian markets will enable us to accelerate efforts to bring VIS-101 to patients and make this innovative therapy available to more patients."
On October 30, 2025, Everest Medicines entered into a collaboration agreement with Visara, under which Everest acquired an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries.
Most Read
Bio Jobs
News